港股市场速览：小盘风格与医药板块显著上涨

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The report highlights significant increases in small-cap stocks and the pharmaceutical sector, with the Hang Seng Index showing a slight decline of 0.4% while the Hang Seng Composite Index increased by 0.4% [1] - The performance of various sectors is notably mixed, with the pharmaceutical sector rising by 10.0% and the automotive sector declining by 1.7% [1] - Valuation levels across styles and industries show divergence, with the Hang Seng Index's valuation decreasing by 0.8% to 11.7x, while the Hang Seng Composite Index's valuation slightly increased by 0.1% to 11.7x [2] - Earnings expectations for the Hang Seng Index have been revised upward by 0.3%, indicating a generally positive outlook despite significant sectoral differences [3] Summary by Sections Market Performance - The Hang Seng Index decreased by 0.4%, while the Hang Seng Composite Index increased by 0.4% [1] - Mid-cap stocks outperformed small-cap and large-cap stocks, with mid-cap stocks rising by 3.7% and small-cap stocks by 3.4% [1] Valuation Levels - The valuation of the Hang Seng Index decreased by 0.8% to 11.7x, while the Hang Seng Composite Index's valuation increased by 0.1% to 11.7x [2] - The biotechnology sector saw a significant valuation increase of 14.0% to 29.5x, while the automotive sector's valuation decreased by 3.6% to 13.8x [2] Earnings Expectations - The earnings per share (EPS) for the Hang Seng Index increased by 0.3%, with the Hang Seng Composite Index's EPS rising by 0.4% [3] - The consumer services sector saw the largest EPS upward revision of 8.2%, while the pharmaceutical sector experienced a downward revision of 5.9% [3]